Compare AbCellera Biologics Inc (ABCL) vs KB Financial Group, Inc. (KB) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbCellera Biologics Inc vs KB Financial Group, Inc. — how do they compare? AbCellera Biologics Inc trades at $7.15 (market cap $2.35B), while KB Financial Group, Inc. trades at $115.25 (market cap $39.97B). The key difference: KB Financial Group, Inc. is far larger — about 17× AbCellera Biologics Inc's market cap, and KB Financial Group, Inc. pays a 2.72% dividend while AbCellera Biologics Inc pays none. Which is the better fit depends on your goals.
| ABCL | KB | |
|---|---|---|
Market Cap | $2.35B | $39.97B |
Sector | Health | Financials |
52-Week High | $8.12 | $118.21 |
52-Week Low | $2.78 | $77.50 |
Enterprise Value | $1.99B | — |
Dividend Yield | — | 2.72% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.
The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.
KB trades at $115.48, up 5.61% today, showing strong momentum near its 52-week high. Recent quarters have consistently beaten earnings expectations, with Q1 2026 EPS of $3.49 surpassing estimates. The stock exhibits bullish technical signals with moving averages supporting upward trends, while fundamentals reveal robust revenue growth to $21.23T in 2025 and a healthy net income margin of 27.82%.
Outlook remains positive given earnings beats and valuation appeal with a P/E of 10.95, though risks include volatile cash flows and high interest expenses. Analyst sentiment is mixed with 33% buy ratings, suggesting cautious optimism for continued performance if execution aligns with growth targets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About KB Financial Group, Inc.
KB Financial is the parent company of KB Kookmin Bank, Korea's largest commercial bank, with a 13.1% share of loans as of 2021. Its predecessor banks were established in the 1960s as government policy banks and privatized in the 1990s. Its credit card subsidiary KB Kookmin Card is the number-three player behind Shinhan Card and Samsung Card. KB has in recent years expanded its nonbank business by buying LIG Insurance and Hyundai Securities, making KB a top-five player in nonlife insurance and in securities, and most recently by buying Prudential Life Insurance Korea. It also has KB Capital, which provides leasing and installment finance.
Read more on KB →
